RxDoctor Payments Data

Kalina Cordova

Acute Care · Albuquerque, NMNPI 1275193724

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,262 of the $3,670 with a category attached, or 88.9%. 16 manufacturers reported payments, led by Boston Scientific at 38.8% of the total. 2025 is the largest year on record at $2,265, 9.7 times the $235 reported in 2022. Among acute care clinicians in NM with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,670in general payments, 2019–2025

Across 37 payments — averaging $99.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • AstraZeneca$505
  • Novartis$284
  • Abiomed$240
  • Heartflow, Inc.$186
  • Edwards Lifesciences$146
  • plus $886 from 10 others

What the payments were for

  • Travel & lodging$40811%
  • Food & beverage$3,26289%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,670 in reported general payments places this provider in the 90th percentile of 132 acute care providers in New Mexico.

See all acute care providers in New Mexico

Medicare billing

Part B allowed, 2024
$13,656
Medicare patients
117
Services billed
148

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan61$74,243
XareltoRivaroxaban40$54,652
EliquisApixaban30$49,190
FarxigaDapagliflozin Propanediol22$25,286
Metoprolol Succinate146$2,140
Bumetanide61$1,942
Atorvastatin Calcium123$1,587
Potassium Chloride37$1,029
Carvedilol63$949
Diltiazem 24hr Er (Cd)Diltiazem Hcl22$821
Lisinopril61$789
Flecainide Acetate18$781
Spironolactone47$611
Furosemide70$608
Ezetimibe18$608

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$284$74,24361 claims
AstraZenecaFarxiga$505$25,28622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 132 acute care providers in New Mexico.

Other acute care in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →